Bampidirsen
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FORWARD-53 NCT04906460 · Duchenne Muscular Dystrophy Registry: NCT04906460 | 1/2 | Part A: Safety: Proportion of patients with adverse events (AEs) (Day 1 (initial dose) up to 24 weeks after the last dose of Part A); Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531 (At Week 26 and at Week 50 of Part B); Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531 (At Baseline and following 24 weeks of treatment in Part C) 2026-10 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Duchenne Muscular Dystrophy: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bampidirsen: this drug | Phase 1/2 | RNA / oligonucleotide | DMD exon 53 | not yet graded | No reviewed efficacy summary in this indication | |
| Givinostat | Approved | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| Deramiocel | Phase 3 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RGX-202 | Phase 2/3 | Gene therapy / editing | Dystrophin (microdystrophin transgene) | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Zotadirsen | Phase 2 | RNA / oligonucleotide | DMD exon 44 | not yet graded | No reviewed efficacy summary in this indication | |
| Nivudirsen (BMN 351) | Phase 1/2 | RNA / oligonucleotide | DMD exon 51 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bampidirsen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
March 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent